1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Revisiting the pharmaceuticalisation of pandemic influenza using Lukes’ framework of power
(
- Contribution to journal › Article
-
Mark
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
(
- Contribution to journal › Article
- 2018
-
Mark
Categorical and anti-categorical approaches to US racial/ethnic groupings: revisiting the National 2009 H1N1 Flu Survey (NHFS)
(
- Contribution to journal › Article
-
Mark
Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics
(
- Contribution to journal › Article
-
Mark
Regulatory scientists' work has important ramifications for public health and should be open to public scrutiny
(
- Contribution to journal › Letter
- 2017
-
Mark
Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews
(
- Contribution to journal › Article
- 2016
-
Mark
Regulating Pharmaceutical Industry Marketing: Development, Enforcement and Outcome of Marketing Rules
(
- Contribution to journal › Article
-
Mark
Unhealthy marketing of pharmaceutical products: An international public health concern
(
- Contribution to journal › Article
-
Mark
Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
(
- Contribution to journal › Article
- 2015
-
Mark
Många allvarliga brott mot regler när läkemedel marknadsförs
(
- Contribution to journal › Letter